Merck & Co. Says European Regulators Recommend Approval of HIV Drug Isentress
November 19, 2007
European regulators have recommended approval of Merck & Co.'s HIV drug Isentress in combination with other antiretroviral (ARV) treatments, the drug maker announced on Thursday. Isentress is designed to treat HIV in adult patient who have already been receiving ARVs. The recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency will be taken into account by the European Commission, which makes the final decision on whether to approve the drug for use in the European Union.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.